DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol

Information source: Janssen-Cilag Farmaceutica Ltda.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Contraception

Intervention: Norelgestromine (NLGM)/ethinyl estradiol (EE) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Janssen-Cilag Farmaceutica Ltda.

Official(s) and/or principal investigator(s):
Janssen-Cilag Farmaceutica Ltda. Clinical Trial, Study Director, Affiliation: Janssen-Cilag Farmaceutica Ltda.

Summary

The purpose of this study is to evaluate the contraceptive efficacy, safety, cycle control, compliance, and subject satisfaction of the transdermal contraceptive system, norelgestromine and ethinyl estradiol (NLGM / EE).

Clinical Details

Official title: An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome:

Pregnancy Rate Determined by Pearl Index

Pregnancy Rate Determined by Table of Life Analysis

Secondary outcome:

Percentage of Participants With Breakthrough Bleeding and/or Spotting

Compliance Score

Percentage of Participants With Response to Satisfaction Questionnaire

Detailed description: A multicenter, open label, descriptive study. Five hundred requiring contraception will receive the weekly transdermal contraceptive patch for 6 cycles. At the baseline and after the 1st, 3rd and 6th cycles, satisfaction with the method will be assessed. The contraceptive efficacy will be assessed by the Pearl Index and by life table analysis. To assess satisfaction with the weekly transdermal contraceptive patch, this method will be compared to the previous contraceptive method. Adhesion, cycle control, safety and efficacy are secondary outcomes. Treatment duration: 6 cycles (4 weeks each). The subject will wear a 20 cm2 contraceptive transdermal patch for one full week, apply a fresh patch for week 2, and a third patch for week 3. The fourth week will be patch-free. Each patch deliveries 150 mcg of NLGM and 20 mcg of EE per day.

Eligibility

Minimum age: 21 Years. Maximum age: 45 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Healthy adult females who meet the following selection criteria: Have regular menses

occuring every 25-35 days

- Acceptable body mass (< 30) and the weight is < 90 kg

- Has completed her last term pregnancy at least 4 months prior to study admission, is

not lactating and has at least one normal menstrual period since her last pregnancy and not breast feeding

- Has a sitting blood pressure systolic < 140 mm/Hg and diastolic < 90 mm/Hg.

Exclusion Criteria:

- Has not received a DepoProvera injection or any other depot hormone injection within

six months prior to the screening visit

- Has not used / or in current use of barbiturates, antiepileptics, rifampin,

griseofulvin, Hypericum perforatum, or other hepatic enzyme-inducing drugs within 30 days prior to the pre-study visit

- Has not a uncontrolled disorder

- No women over the age 35 who smoke.

Locations and Contacts

Belo Horizonte, Brazil

Botucatu, Brazil

Brasilia, Brazil

Curitiba, Brazil

GoiĆ¢nia, Brazil

Porto Alegre, Brazil

Ribeirao Preto, Brazil

Sao Paulo, Brazil

Sorocaba, Brazil

Ciudad De Mexico, Mexico

Mexico, Mexico

Monterrey, Mexico

Additional Information

Starting date: February 2003
Last updated: May 14, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017